{
    "clinical_study": {
        "@rank": "115944", 
        "arm_group": [
            {
                "arm_group_label": "Part I Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID"
            }, 
            {
                "arm_group_label": "Part I BG00012", 
                "arm_group_type": "Experimental", 
                "description": "BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID"
            }, 
            {
                "arm_group_label": "Part II BG00012", 
                "arm_group_type": "Experimental", 
                "description": "Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter study conducted in 2 parts:\n\n      The primary objective in Part I of this study is to determine the efficacy of BG00012\n      (dimethyl fumarate, DMF) on inflammatory brain magnetic resonance imaging (MRI) lesion\n      activity (Gadolinium-enhancing lesions) when compared with placebo from 4 scans performed at\n      Weeks 12, 16, 20, and 24 in participants with Relapsing Remitting Multiple Sclerosis (RRMS)\n      including participants from the Asia-Pacific region.\n\n      The secondary objectives in Part I of this study in this study population are to determine\n      whether BG00012, when compared with placebo over 24 weeks, is effective in reducing the\n      cumulative number of new Gadolinium-enhancing lesions from Baseline to Week 24; reducing the\n      number of new or newly enlarging T2 hyperintense lesions on brain MRI scans at Week 24\n      compared with Baseline.\n\n      The primary objective in Part II (open label) of this study is to evaluate the long-term\n      safety profile of BG00012 in eligible participants from Part I."
        }, 
        "brief_title": "An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)", 
        "completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Relapsing-Remitting Multiple Sclerosis", 
            "Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Inclusion Criteria for Part I:\n\n               -  Must have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS).\n\n               -  Must have a baseline Expanded Disability Status Scale (EDSS) score between 0.0\n                  and 5.0, inclusive.\n\n        Key Inclusion Criteria for Part II:\n\n        \u2022 Subjects who participated in and completed Part I per protocol.\n\n        Key Exclusion Criteria:\n\n          -  Other chronic disease of the immune system, malignancies, acute urologic, pulmonary,\n             gastrointestinal disease.\n\n          -  Pregnant or nursing women.\n\n        NOTE:  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "202", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838668", 
            "org_study_id": "109MS305", 
            "secondary_id": "2013-004533-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part I Placebo", 
                "description": "Placebo orally twice a day.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part II BG00012", 
                    "Part I BG00012"
                ], 
                "description": "BG00012 120 mg capsules.", 
                "intervention_name": "BG00012 (dimethyl fumarate)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DMF", 
                    "dimethyl fumarate"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dimethyl fumarate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ehime", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ibaraki", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ishikawa", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iwate", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miyagi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niigata", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yamaguchi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonngi", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taoyuan", 
                        "country": "Taiwan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis", 
        "overall_contact": {
            "email": "neurologyclinicaltrials@biogenidec.com", 
            "last_name": "Biogen-Idec Investigator"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Ministry of Food and Drug Safety", 
                "Taiwan: Department of Health", 
                "Czech Republic: State Institute for Drug Control", 
                "Japan: Pharmaceuticals and Medical Devices Agency (PMDA)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Total number of new Gadolinium-enhancing lesions over 4 scans at Weeks 12, 16, 20, and 24.", 
                "safety_issue": "No", 
                "time_frame": "Part I (Week 24)"
            }, 
            {
                "measure": "Incidence of treatment-emergent adverse events and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Part II (Up to 4.5 years)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838668"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cumulative number of new Gadolinium-enhancing lesions from Baseline to Week 24", 
                "safety_issue": "No", 
                "time_frame": "Part I (Week 24)"
            }, 
            {
                "measure": "Number of new or newly enlarging T2 hyperintense lesions at Week 24 compared with Baseline", 
                "safety_issue": "No", 
                "time_frame": "Part I (Week 24)"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}